iShares JPMorgan USD Emerging Markets Bond ETF vs Medtronic PLC — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $91.59 (market cap $12.87B), while Medtronic PLC trades at $87.92 (market cap $112.24B). The key difference: Medtronic PLC is far larger — about 8.7× iShares JPMorgan USD Emerging Markets Bond ETF's market cap, and Medtronic PLC pays a 3.28% dividend while iShares JPMorgan USD Emerging Markets Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares JPMorgan USD Emerging Markets Bond ETF for 50 Days and Medtronic PLC for 63 Days on average.
| EMB | MDT | |
|---|---|---|
Market Cap | $12.87B | $112.24B |
Volume | 14,946,002 | 105,663,236 |
Sector | Fixed Income | Health |
52-Week High | $97.74 | $105.35 |
52-Week Low | $90.14 | $73.75 |
Typical Hold Time | 50 Days | 63 Days |
Enterprise Value | — | $131.58B |
Dividend Yield | — | 3.28% |
Signals from Pluang's Aura AI — not financial advice
EMB trades at $90.78, down 0.19% with a bearish technical signal from moving averages. The stock shows neutral oscillator readings with RSI at oversold levels. Recent dividend declarations of $0.41-$0.44 per share provide income support, though key valuation ratios remain unavailable for analysis. Technical indicators suggest the stock is testing support levels near $90-$91.
The outlook remains cautious given the bearish technical momentum and limited fundamental data visibility. Income investors may find value in the dividend yield, but the lack of current financial metrics and bearish technical signals suggest near-term pressure. Market sentiment appears mixed with fixed income ETFs seeing inflows while emerging market bonds face AI-driven yield pressures.
Medtronic (MDT) trades at $85.51, down 1.81% on the day, showing bearish technical signals despite strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters with Q3 2026 results pending, while maintaining robust profitability margins of 65% gross and 14% net. Recent news highlights the company's 49-year dividend growth streak and new product approvals, though technical indicators show selling pressure with the stock trading near support at $85.
MDT presents a compelling value opportunity with a 3.2% dividend yield and 14% upside to the $97.80 consensus target, though near-term technical weakness and increasing debt levels warrant caution. The company's consistent earnings beats and medical device market leadership support long-term growth, while regulatory approvals for new systems provide catalysts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →